A research team from Roswell Park Comprehensive Cancer Center, Mimivax LLC and Cleveland Clinic is working on a clinical trial for glioblastoma patients.
Glioblastoma is the most common and aggressive form of brain cancer in adults.
The team is studying whether or not a adding a medicine, developed in Buffalo at Roswell Park, called SurVaxM is aiding in the treatment of newly diagnosed glioblastoma patients. The team will share their findings at the 2018 American Society of Clinical Oncology annual meeting in Chicago.
Researchers have found that in their clinical testing, when SurVaxM is included in treatment, it appears to be safe, effective and worthy of further studying.
They found that 91% of patients receiving SurVaxM as part of this hybrid therapy were still living 12 months after starting treatment, compared to 61% in a historical analysis of patients treated with standard therapy alone. 96% of patients achieved six-month progression-free survival, compared to 54% among the historical comparison group. 13 of 63 patients continue to be without progression a year or longer into their participation in the study.
